top of page
Search

Primary Progressive Multiple Sclerosis (PPMS) Market Size, Epidemiology, Leading Companies, Drugs

  • Writer: Ankit Nigam
    Ankit Nigam
  • Oct 28, 2020
  • 3 min read

DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Primary Progressive Multiple Sclerosis (PPMS), historical and forecasted epidemiology as well as the Primary Progressive Multiple Sclerosis (PPMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

· As per the National Multiple Sclerosis Society, about 15% of the total estimated MS patients in the United States with multiple sclerosis (MS) have the primary progressive form of the disease (PPMS).

· According to a study by Costa-Arpín et al. (2020), in a Spanish cohort, 71.17% had relapsing-remitting MS, 16.55% secondary progressive MS, 7.59% primary progressive MS, and 0.69% progressive relapsing MS.

· As per the estimates provided by Columbia University Medical Center (2018), on average, people with the primary progressive form of MS start having symptoms between ages 35 and 39.

· According to a review article titled “Primary Progressive Multiple Sclerosis” published by Giovannon et al. (2012), the female to male ratio is generally 1:1 with regard to PPMS and 2 or even 3:1 for relapse onset disease. As seen by changes in the sex ratio, the increasing female preponderance of MS seems to be driven by relapse-onset disease, with the incidence of PPMS remaining relatively constant.

  • The report covers the descriptive overview of Primary Progressive Multiple Sclerosis (PPMS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the Primary Progressive Multiple Sclerosis (PPMS) epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Primary Progressive Multiple Sclerosis (PPMS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of Primary Progressive Multiple Sclerosis (PPMS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Primary Progressive Multiple Sclerosis (PPMS) market

Primary-Progressive Multiple Sclerosis (PPMS) is a neurodegenerative disease that interferes with the brain's ability to control the body. There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe. PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.

PPMS can be further characterized at different points in time as either active (with an occasional relapse and/or evidence of new MRI activity) or not active, as well as with progression (evidence of disease worsening on an objective measure of change over time, with or without relapse or new MRI activity) or without progression.

The occurrence and severity of PPMS symptoms vary with each person. Symptoms include headaches, pain in the legs and feet, back pain, muscle spasms, trouble in walking, vision problems, etc. In addition, this condition affects men and women equally.

· MedDay Pharma

· MediciNova

· Mapi Pharma

· Brainstorm-Cell Therapeutics

· And Many Others

· GA Depot

· MN-166

· MD1003

· NurOwn

· And Many Others

1. Key Insights

2. Executive Summary of Primary Progressive Multiple Sclerosis (PPMS)

3. Competitive Intelligence Analysis for Primary Progressive Multiple Sclerosis (PPMS)

4. Primary Progressive Multiple Sclerosis (PPMS): Market Overview at a Glance

4.1. Primary Progressive Multiple Sclerosis (PPMS) Total Market Share (%) Distribution in 2017

4.2. Primary Progressive Multiple Sclerosis (PPMS) Total Market Share (%) Distribution in 2030

5. Primary Progressive Multiple Sclerosis (PPMS): Disease Background and Overview

6. Patient Journey

7. Primary Progressive Multiple Sclerosis (PPMS) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Primary Progressive Multiple Sclerosis (PPMS) Treatment and Management

8.2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Primary Progressive Multiple Sclerosis (PPMS) Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Primary Progressive Multiple Sclerosis (PPMS): Seven Major Market Analysis

13.1. Key Findings

13.2. Primary Progressive Multiple Sclerosis (PPMS) Market Size in 7MM

13.3. Primary Progressive Multiple Sclerosis (PPMS) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Primary Progressive Multiple Sclerosis (PPMS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for

Browse through our vast repository from here.

Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: info@delveinsight.com Phone: +19193216187 City: Albany State: New York Country: United States Website: https://www.delveinsight.com/

 
 
 

Recent Posts

See All

Comments

Post: Blog2_Post

Subscribe Form

Thanks for submitting!

  • Facebook
  • Twitter
  • LinkedIn

©2020 by DelveInsight Pharma News. Proudly created with Wix.com

bottom of page